Provided by Tiger Trade Technology Pte. Ltd.

Corbus Pharmaceuticals

11.30
-0.0100-0.09%
Post-market: 11.330.0300+0.27%19:30 EDT
Volume:392.19K
Turnover:4.43M
Market Cap:218.56M
PE:-1.86
High:11.55
Open:11.36
Low:10.96
Close:11.31
52wk High:20.56
52wk Low:7.12
Shares:19.34M
Float Shares:17.42M
Volume Ratio:0.51
T/O Rate:2.25%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-6.0889
EPS(LYR):-5.9000
ROE:-95.58%
ROA:-53.00%
PB:2.14
PE(LYR):-1.92

Loading ...

Corbus Pharmaceuticals is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Aug 07

Corbus Pharmaceuticals Holdings : Oppenheimer Cuts Target Price to $48 from $52

THOMSON REUTERS
·
Aug 07

Corbus Pharmaceuticals Holdings, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 06

Corbus Pharmaceuticals Q2 EPS $(1.81) Misses $(1.26) Estimate

Benzinga Earnings
·
Aug 06

Corbus Q2 FY26 Net Loss Widens to $35.04 Million; Loss Per Share Increases to $1.81

Reuters
·
Aug 06

Corbus Pharmaceuticals Holdings Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Aug 06

Corbus Pharmaceuticals Holdings Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Aug 05

Corbus Pharma CMO Nicacio Leonardo Viana Files Initial Beneficial Ownership Statement

Reuters
·
Aug 05

Corbus reports last patient completes last visit in CANYON-1 trial

TIPRANKS
·
Aug 04

Corbus Says Phase 1b Canyon-1 Obesity Trial of CRB-913 Reaches Last Patient Last Visit

Reuters
·
Aug 04

Corbus Pharmaceuticals Announces Last Patient Last Visit in Canyon-1 Study of Crb-913 for the Treatment of Obesity

THOMSON REUTERS
·
Aug 04

Corbus Pharmaceuticals Holdings Inc Expected to Post a Loss of $1.26 a Share - Earnings Preview

Reuters
·
Jul 31

Corbus Pharmaceuticals Holdings Inc. Stock Outperforms Competitors Despite Losses on the Day

Dow Jones
·
Jul 30

Corbus Pharmaceuticals announces FDA clearance to initiate TEMPO-1 trial

TIPRANKS
·
Jul 28

Corbus Pharmaceuticals Announces FDA Clearance to Initiate Tempo-1 Registrational Study of Crb-701 in Patients with 2L Oropharyngeal Cancer

THOMSON REUTERS
·
Jul 28

Corbus Pharmaceuticals Holdings Inc: Expects to Initiate Enrollment in Tempo-1 in September 2026

THOMSON REUTERS
·
Jul 28

Corbus Pharmaceuticals Announces FDA Clearance to Initiate TEMPO-1 Registrational Study of CRB-701 in Patients with 2L Oropharyngeal Cancer

GlobeNewswire
·
Jul 28

Corbus Pharmaceuticals Holdings Inc. Stock Outperforms Competitors Despite Losses on the Day

Dow Jones
·
Jul 25

Corbus Pharmaceuticals Holdings Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Jul 24

Corbus Pharmaceuticals Holdings Inc. Stock Outperforms Competitors Despite Losses on the Day

Dow Jones
·
Jul 23